Clinical characteristics of patients who preferred migraine prevention treatment with CGRP monoclonal antibodies

被引：0
|
作者：
Vashchenko, N. [1 ,2 ]
Skorobogatykh, K. [2 ]
Azimova, J. [2 ]
Korobkova, D. [2 ]
机构：
[1] Sechenov Univ, Dept Neurol, Moscow, Russia
[2] Univ Headache Clin, Moscow, Russia
来源：
JOURNAL OF HEADACHE AND PAIN | 2021年 / 22卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P0341
引用
收藏
页码：122 / 122
页数：1
相关论文
共 50 条
  • [31] Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
    Lampl, Christian
    Seng, Elizabeth
    Vincent, Maurice
    Lenderking, William R.
    Hoyt, Margaret
    Hetherington, Lucinda
    Ladd, Mary Kate
    Malley, Karen
    Chen, Jun
    Viktrup, Lars
    JOURNAL OF HEADACHE AND PAIN, 2024, 25 (01):
  • [32] Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world
    Caronna, Edoardo
    Gallardo, Victor Jose
    Egeo, Gabriella
    Vazquez, Manuel Millan
    Castellanos, Candela Nieves
    Membrilla, Javier A.
    Vaghi, Gloria
    Rodriguez-Montolio, Joana
    Fabra, Neus Fabregat
    Sanchez-Caballero, Francisco
    Sanchez, Alex Jaimes
    Munoz-Vendrell, Albert
    Oliveira, Renato
    Garate, Gabriel
    Gonzalez-Osorio, Yesica
    Guisado-Alonso, Daniel
    Ornello, Raffaele
    Thunstedt, Cem
    Fernandez-Lazaro, Iris
    Torres-Ferrus, Marta
    Alpuente, Alicia
    Torelli, Paola
    Aurilia, Cinzia
    Pere, Raquel Lamas
    Castrillo, Maria Jose Ruiz
    De Icco, Roberto
    Sances, Grazia
    Broadhurst, Sarah
    Ong, Hui Ching
    Garcia, Andrea Gomez
    Campoy, Sergio
    Sanahuja, Jordi
    Cabral, Goncalo
    Blasco, Isabel Beltran
    Waliszewska-Prosol, Marta
    Pereira, Liliana
    Layos-Romero, Almudena
    Luzeiro, Isabel
    Dorado, Laura
    Escudero, Maria Rocio Alvarez
    May, Arne
    Lopez-Bravo, Alba
    Martins, Isabel Pavao
    Sundal, Christina
    Irimia, Pablo
    Ros, Alberto Lozano
    Gago-Veiga, Ana Beatriz
    Juanes, Fernando Velasco
    Ruscheweyh, Ruth
    Sacco, Simona
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2024, 95 (10): : 927 - 937
  • [33] Monoclonal antibodies for the prevention of migraine
    Raffaelli, Bianca
    Neeb, Lars
    Reuter, Uwe
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (12) : 1307 - 1317
  • [34] Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
    Pellesi, Lanfranco
    Guerzoni, Simona
    Pini, Luigi Alberto
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2017, 6 (06): : 534 - 547
  • [35] CGRP antibodies: the Holy Grail for migraine prevention?
    Pascual, Julio
    LANCET NEUROLOGY, 2015, 14 (11): : 1066 - 1067
  • [36] Efficacy and Safety of Anti- CGRP Monoclonal Antibodies for Migraine Preventative Treatment
    Salim, A.
    Najjar, A.
    Ahmed, Z.
    Mata, I
    HEADACHE, 2023, 63 : 131 - 131
  • [37] Efficacy and Safety of Anti-CGRP Monoclonal Antibodies for Migraine Preventative Treatment
    Salim, Amira
    Najjar, Atia
    Ahmed, Zubair
    Mata, Ignacio
    NEUROLOGY, 2023, 100 (17)
  • [38] The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine
    Fred Cohen
    Hsiangkuo Yuan
    E. M. G. DePoy
    Stephen D. Silberstein
    Neurotherapeutics, 2022, 19 : 922 - 930
  • [39] The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine
    Cohen, Fred
    Yuan, Hsiangkuo
    DePoy, E. M. G.
    Silberstein, Stephen D.
    NEUROTHERAPEUTICS, 2022, 19 (03) : 922 - 930
  • [40] Real-World Effectiveness of Eptinezumab after Treatment with Subcutaneous CGRP Monoclonal Antibodies in Patients with Migraine
    Casaletto, Emily
    Yang, Qiu Zi
    Waters, John
    Curran, John
    Lowe, Austin
    Yuan, Hsiangkuo
    NEUROLOGY, 2023, 100 (17)
12345